Toronto, Ontario--(Newsfile Corp. - May 8, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX) ("Therma" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to provide an update on the significant progress achieved at InStatin over the past few months, focused on the development of inhaled statin therapies for respiratory conditions.

A key development at InStatin is the appointment of Professor Sir Peter Barnes as a strategic advisor. Sir Peter is a globally recognized respiratory clinician and innovative scientist renowned in the fields of asthma and Chronic Obstructive Pulmonary Disease (COPD). His extensive expertise and enthusiasm for inhaled statins align strongly with Therma Bright's vision for InStatin.

On the preclinical front, InStatin has successfully completed a rodent pharmacokinetic (PK) study to determine the duration of lung exposure with one of its selected statins. Furthermore, Dr. Amir Zeki has been awarded a significant grant from the National Institutes of Health (NIH) to conduct a crucial statin efficacy study in monkeys utilizing a well-established ozone sensitization model. The study will provide critical data on the therapeutic potential of InStatin's technology in a relevant preclinical model.

The well-established safety profile of statins and InStatin's initial focus on mild to moderate asthma is a strategic entry point, suggesting that regulatory approval in asthma may be a more expeditious pathway compared to the larger COPD market.

In parallel with its preclinical advancements, InStatin is actively strengthening its formulation and intellectual property (IP) position. The Company has engaged Mike Rafa of Rafa Patent Consulting, LLC, an experienced IP attorney, to support its IP development efforts.

Therma Bright is highly encouraged by the progress at InStatin, the invaluable addition of Professor Sir Peter Barnes as a strategic advisor, and the advancements in preclinical studies and IP development. InStatin remains committed to advancing towards clinical trials and realizing its potential to address significant unmet needs in the treatment of respiratory diseases.

About Therma Bright Inc.

Therma Bright develops and partners on cutting-edge diagnostic and medical device technologies that address key healthcare challenges. Therma Bright Inc. trades on the (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). Visit: www.thermabright.com.

Follow us X

FORWARD-LOOKING STATEMENTS
Certain statements in this news release constitute "forward-looking" statements. These statements relate to future events such as current and future development of InStatin and related technology as described in the news release. All such statements involve substantial known and unknown risks, uncertainties and other factors which may cause the actual results to vary from those expressed or implied by such forward-looking statements. Forward-looking statements involve significant risks and uncertainties, they should not be read as guarantees of future performance or results, and they will not necessarily be accurate indications of whether such results will be achieved. Actual results could differ materially from those anticipated due to several factors and risks. Although the forward-looking statements contained in this news release are based upon what management of the Company believes are reasonable assumptions on the date of this news release, the Company cannot assure investors that actual results will be consistent with these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities regulations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/251233